Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Lupus / April 2006

Tip: Looking for answers? Try searching our database.

ABOUT SLE STUDY...

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
julia - 28 Apr 2006 23:40 GMT
DERMATOVENEROLOGY.
ABOUT SLE STUDY.
AUTHOR A LECTURE M.D.REBROV FROM SARATOV PUBLIC  MEDICINAL UNIVERSITY.

SLE-IS a disease,developming on basis of geneticaly due imperfection a
immunoregulatory processes,leading to a forming immunocomlex
inflammatory,consequence of which and being the defeate of many  organs
and systems.
Frequency a sle 4-250 cases for 100 000 population/year.In usa annual
prevalence a sle is =50-70 a new cases for 1 million population.
A more 70 percent with sle is age 14-40 year,peak of prevalence 14-25
y.old.COrrelation :womens and mans from 8:1 to 10:1,childrens -3:1.
ETHIOLOGY.
A staring role RNA-CONTAINING AND SLOW VIRUSES/RETROVIRUSES/:
forming antibodies to DNA and RNA-containing viruses.
presence paramixoviruse cytoplasmatic inclusions.
presence tubuloreticular inclusions in epithelium and inside a
lymphocytes.
HAS AND MEANING:genetic factors/HLA-A1,B8,DR2,DR3/.

endocrine factors/oestrogens influence/.
factors from environmen/ultraviolet rays,influence ,like bacterial and
viruse infection,drugs/
SLE-IS immunocomplex disease,for which is charactered uncontrolled
production the antibodies,forming immune complexs,consequensing a
different signs of disease.

Circulating immune complexs laying  in subendothelial layer a basal
membrane of vessels a many organs.

A place of fixation a diposits /skin,kidneys,choroidal plexus,serous
membranes/defining a such antigene parameter ,or antibody,like a
size,charge ,molecular configuration,immunoglobulin class.

CLINICAL PICTURE.

Skin defeat-is different ,in 20-25 percent skin syndrome-a begin sign
of disease,in 60-70 percent-is appearances on a different stages of
disease.

Observing 28 variants  a skin changes in sle from erythematosis spot to
difficult bullosa  rashs.

Jont problems and periarticular tissues-arthralgias in 100
percent,tendinitis,tendovaginitis,aseptic necrosis a bones-in 25
percent.

myalgias in 45-45 percent.

LUNG PROBLEMS:

in 50-80 percent  dry and exudative pleuritis.
vasculitis.
pneumonitis.
HEART AND VESSEL PROBLEMS:

dry and exudative pericarditis.
myocarditis.
endocarditis-mitral ,aortic,tricuspid  valve.
arteries a small and middle gauges.
aorta and her branches.
thrombosis a  great vessels.
trombophlebitis.
gastrointestinal and liver in 50 percent cases.

gullet defeat-10-15 percent.
ishemia of walls a stomach and intestine.
hepatomegaly.
KIDNEY DEFEAT:

LUPUS NEPHRITIS,LIKE ACTIVE FORMS:

fastprogressing ,
nephriti with nephrotic syndrome.
nephritis with marked nephritic syndrome.
nephritis with minimal urine syndrome.

CNS DEFEATE:

vasculopathy-65 percent.
thrombosis and natural vasculitis-15 percent.
infarctions and hemmorhagias.
antibody and immunocomplex inflammatory.
CLINICAL DISPLAYS:

headache.
psychical dissorders.
defeat of scull and peryphery nerves.
seizures.
visual breachs.
transient breachs a cerebral circulation of the blood.
LABORATORY RESEARCHS.

le-cells.
antinuclear antibodies.
antibodies to twospiral DNA.
antibodies to onespiral DNA.
anemia normocyte and
normochrome,leucopenia,lymphocytopenia,thrombocytopenia.

CLASSIFICATION A SLE.

VARIANT OF COURSE:ACUTE,SUBACUTE,CHRONIC.

A DEGREE OF ACTIVITY:1-MINIMAL,2-MODERATE,3-HIGH.

ALSO INCUDING AND ARA/1982/.
julia - 29 Apr 2006 00:36 GMT
CONTINUATION ABOUT A SLE STUDY.
A treatment of sle.
SLE-IS autoimmune disease,at the heart  of pathogenesis is lies a
defects of immunoregulation,leading to uncontrolling hyperproduction
autoantibodies to components a own tissue and development a chronic
inflammatory,affecting of many organs and systems.
For sle is using:
base methods of pathogenetic therapy,
methods of intensive therapy,
additional methods of pathogenetic therapy.
supporting remedies.
ABSOLUTE INDICATIONS TO TREATMENT A GLUCOCORTICOSTEROIDA IN SLE:

HIGH INFLAMMATORY ACTIVITY.
DEFEAT OF INTERNAL ORGANS,IN A FIRST PLACE NEPHRITIS.
HEMATOLOGIC DISSORDERS.
Suppressing prednisolonum dose  1-1,5 mg/day ,on average  approximately
60 mg/day,duration 4-8 weeks with gradual decreasing  to supporting
dose 5-10 mg/day,which is take a long time ,often for a term of
life,transfer  from prednisolonum dose 60 mg/day  to dose 35-40 mg/day
is =3 month,but to dose 15-20 mg/day -6 months.

A BASE REMEDIES FOR SLE TREATMENT.

GLUCOCOCRTOCOSTERIODS FOR INTERNAL TAKING-a most often taking
prednisolonum,methylprednidolonum,taking-rarely,or like,alternative
-triamcinolon.
PULSE-THERAPY,LIKE GLUCOCORT.FOR INTRAVENOUSE INTRODUCTION -a most
often taking methylprednisolonum.
IMMUNOSUPPRESSANTS-cyclophosphamidum,imuranum,rarely taking,or,like
alternative-chlorbutinum,metotrexatum,cyclosporinum A.
AMINOCHINOLINE DERIVATIVE-plaquenil,rarely,like alternative-delagyl.
A SCHEMES OF TREATMENT A BASE PREPARATIONS FOR SLE TREATMENT.

PREDNISOLONUM,LIKE INSIDE TAKING,FOR SUPPRESSING THERAPY 1-1,5
MG/KG/DAY/ON AVERAGE 50-60 MG/DAY/4-8 WEEKS.
SUPPRTING THERAPY 5-10 MG/DAY/10-15 YEARS,OFTEN FOR A TERM OF LIFE/.
METHYLPREDNISOLONUM FOR INTRAVENOUSE.

SUPPRESSING THERAPY 500-1000 MG IN COMPLIANCE WITH SCHEME A ALTERNATIVE
THERAPY.
SUPPORTING THERAPY-500-1000 MG 1 TIME/MONTH/TO 24 MONTHS/.
CYCLOPHOSPHAMIDUM INTRAVENOUSE.

SUPPRESSING THERAPY 500 MG 1 TIME/WEEK 4 WEEKS OR 1000 MG 1-2 TIME IN
COMBINATION THERAPY OR 200 MG IN1 DAY  10 TIMES/TO A TOTAL DOSE 2000
MG/MONTH/.
SUPPORTING THERAPY -1000 MG 1 TIME/WEEK WITH IMTERVAL INCREASING
BETWEEN INJECTIONS/TO 5 YEARS/.
AZATHIOPRINUM.

SUPRESS.THERAPY-100-150 MG/DAY.
SUPPORT.THERAPY-50-100 MG/DAY/TO 5 YEARS/.
HYDROCHLOROQUNE.

SUPPRESS.THERAPY-600 MG/DAY.
SUPPORT.THERAPY.-200-400 MG/DAY/LONG TIME,FOR A TERM OF LIFE/.
julia - 29 Apr 2006 11:49 GMT
INTENSIVE THERAPY FOR SLE.
A BASE INDICATION TO USE A PULSE THERAPY:
active lupus-nephritis/especially with nephrotic syndrome,artherial
hyperthension,fast creatinine rising/.
acute difficult defeat of
cns/meningoencephalitis/,encephalopolyradiculoneuritis,transversal
myelitis.
hematologic crisis,deep thrombocytopenia.
ulcer-necrotic vasculitis.
pulmonary vasculitis.
high disease activity,resistance to therapy.
A base method for intensive therapy a sle-pulse-therapy-taking
methylprednisolonum with dose 500-1000 mg/day intravenously.

Doses is less 1000 mg methylprednisol./day is taking in a high level
of side effects -in eldery patients,presence artherial
hyperthension,marked heart failure.

Rarely taking dexamethasonum ,like middle dose 100-150 mg/day by  a
different schemes.

Appropriately taking a following schemes:

monthly introduction 100 mg methylprednisolon.duration 1 year.
combination/with adding 1000 mg cyclophosphamidum/pulse-therapy,like 3
day,so and programm duration 1 year.
A MOST PREVALENT METHODS THE INTENSIVE THERAPY:

classical pulse-therapy 1000 mg methylprednisolon./day intravenously
droply duration 3 consistent days/3000 mg in course/
introduction intravenously a decreasing doses a
methylprednisol./250-500 mg/day/to attainment a summary dose
approximately 3000 mg/in course.
monthly introduction introvenously 1000 mg.methylprednisol.duration
6-12 months.
combination pulse-therapy intravenously 1000 mg methylprednisolonum 3
days running+1000 mg cyclophoshamidum in a 1 st and 2 nd
day/methylprednis.and cyclophosphanum introductioning  in series.
monthly intravenouse introduction 1000 mg methylprednisolonum +100 gr
cyclophosphamidum duration 12 months.
monthly intravenously 1000 mg cyclophosphamidum duration 12 months.
Lower dose a peroral prednisolonum is immediately after conducting a
pulse-therapy a glucocorticosteroid.is a dont recommending/so as it is
a possible temporary abolition syndrome/.
julia - 29 Apr 2006 22:12 GMT
ADDITIONAL METHODS A PATHOGENETIC THERAPY FOR SLE.
Plasmapheresis is a method of choise  in acute conditions and a
extremely  high activity of diseases,resistance to therapy.Course for
plasmapheresis is ,like 3-6 procedures every other day or 2
time/week,and programmely-1 time/month ,like monthly duration 1 year
and more and to avoid syndrome "ricochet" always combining with a
following intravenouse glucocort.introduction and cyclophosphamidum.
Synchrone intensive therapy :conducting plasmapheresis ,like with
course/3-6 procedures/ with a following combination pulse-therapy with
glucocort.and cyclophosphamid.
Right away after a first procedure the plasmapheresis is conducting a
sequential  introduction 1000 mg prednisolon.and 1000 mg
cyclophosphamid.,after repeate seances in a  course treatment  is
introduces intravenously just methylprednis.500-1000 mg.
Synchrone intensive therapy also conducting a monthly duration 12
months and more.
Intravenouse antibody /sandglobulin,normal person s immunoglobulin/:
BLOCKADE FC-RECEPTORS AND FC-DEPEND SYNTHESIS THE AUTOANTIBODIES.
ANTIIDIOPATHIC ACTIVITY.
MODULATION THE ACTIVITY OF T-LYMPHOCYTES AND CYTOKINES SYNTHESIS.
CHANGE A STRUCTURE AND  SOLUBILITY  OF CIRCULATORY IMMUNE COMPLEXS.
Antibody/immunoglobulin/taking ,like intavenously-a method of choise in
marked stable thrombocytopenia,in resistance to lupus nephritis
therapy.Recommending preparation introduction ,like 400-500 mg/kg/day
duration 3-5 sequential days,after 1 time/month fduration 6-12 months.

CYCLOSPORIN A-mechanism of effect in sle is connected with inhibition
of  synthesis a interferon-alfa  and able a suppress of expression  a
ligand CD40 on a membrane of T-LYMPHOCYTES.

In sle cyclospor A .is taking  a less 5 mg/kg/day,more often 2-2,5
mg/kg/day/.Indicated and effectivity in lupus nephritis/with
antiproteinuric effect/,thrombocytopenia,anemia,leucopenia,skin
problems in lupus,refractory to therapy a  polyserositis and pleuritis.

Against a backgroung therapy with cyclosp.A,IS LOWERING A LEVEL OF
ANTICARDIOLIPIN AND ANTITHROMBOCYTE ANTIBODIES.

CYCLOSPORIN A-alternative preparation a second row in intolerance and
inefficency a glucocort.and cytostatic remedies.That remedy also take
in pregnancy.

CELLSEPT-selective immunosuppressant .ACTIVE COMPOUND mycophenol
acid-noncompetitive  inhibitor  a ferment,limiting a synthesis speed of
guasine nucleatid,displays a cytostatic activity.

A most marked antiproliferative effect regarding a T-LYMPHOCYTES,HAS A
ANTIPROLIFERATIVE EFFECT REGARDING A MESANGIAL KIDNEY CELLS,SUPPRESSES
A ANTIBODIES FORMATION.

IN patients with sle-alternative a azathiprinum and cyclophosph.in a
good portability.

"BIOLOGIC AGENTS"-ANTIIDIOTYPICAL MONOCLONAL ANTIBODIES,INTRAVENOUSE
IMMUNOGLOBULIN,MONOCLONAL ANTIBODIES TO IMMUNOGLUBULIN-10.

AUTOLOGOUS TRANSPLANTATION A STEMM CELLS.

http://www.disser.ru   -source.

translate on english from me.
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2009 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.